Advertisement

Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten

Published:December 19, 2019DOI:https://doi.org/10.1053/j.gastro.2019.12.016
      A gluten-free diet (GFD) is the primary treatment for celiac disease (CD), yet many have persistent villous atrophy despite following a strict GFD. Several lines of indirect evidence suggest that persistent villous atrophy reflects ongoing gluten exposure; however, only recently have tools become available to test this hypothesis directly.

      Keywords

      Abbreviations used in this paper:

      CD (celiac disease), GFD (gluten-free diet), GIP (gluten immunogenic peptides), ppm (parts per million)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hall N.J.
        • et al.
        Aliment Pharmacol Ther. 2009; 30: 315-330
        • Murray J.A.
        • et al.
        Gastroenterology. 2017; 152: 787-798.e2
        • Hollon J.R.
        • et al.
        BMC Gastroenterol. 2013; 13: 40
        • Morón B.
        • et al.
        PLoS One. 2008; 3: e2294
        • Bruins Slot I.D.
        • et al.
        Cereal Chem. 2015; 92: 513-521
        • Catassi C.
        • et al.
        Am J Clin Nutr. 2007; 85: 160-166
        • Wahab
        • et al.
        Am J Clin Pathol. 2002; 118: 459-463
        • Blansky B.A.
        • et al.
        Clin Gastroenterol Hepatol. 2019; 17: 2603-2604

      Supplementary References

        • Leffler D.A.
        • et al.
        A validated disease-specific symptom index for adults with celiac disease.
        Clin Gastroenterol Hepatol. 2009; 7: 1328-1334
        • Comino
        • et al.
        Am J Gastroenterol. 2016; 111: 1456-1465

      Linked Article